Publications by authors named "Kenneth Kern"

Claim this Profile
F
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Kenneth A Kern

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Kenneth A Kern

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Kenneth A Kern

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.
Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A Messersmith, Ignacio Garrido-Laguna, Kenneth Kern

Cancer Res Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Victor Manuel Villalobos, Francis Hall, Antonio Jimeno, Lia Gore, Kenneth Kern

Ann Surg Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Zev A Wainberg, Maria Alsina, Heloisa P Soares, Irene Braña, Carolyn D Britten, Kenneth A Kern

Target Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Marzia A Locatelli, Philippe Aftimos, E Claire Dees, Patricia M LoRusso, Mark D Pegram, Kenneth A Kern

Oncotarget· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
Kenneth A Kern

J Oncol Pract· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Diane D Wang, Chunze Li, Wan Sun, Shuzhong Zhang, David R Shalinsky, Kenneth A Kern

Clin Pharmacol Drug Dev· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Wells A Messersmith, Geoffrey I Shapiro, James M Cleary, Antonio Jimeno, Arvind Dasari, Kenneth A Kern

Clin Cancer Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
Thomas Bachelot, Jose A Garcia-Saenz, Sunil Verma, Maya Gutierrez, Xavier Pivot, Kenneth A Kern

BMC Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Giuseppe Curigliano, Xavier Pivot, Javer Cortés, Anthony Elias, Rossano Cesari, Kenneth A Kern

Breast· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
John P Crown, Véronique Diéras, Elzbieta Staroslawska, Denise A Yardley, Thomas Bachelot, Kenneth A Kern

J Clin Oncol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Fatima Cardoso, Jean-Luc Canon, Dino Amadori, Daniela Aldrighetti, Jean-Pascal Machiels, Kenneth A Kern

Breast· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Denise A Yardley, E Claire Dees, Stephen D Myers, Sherry Li, Paul Healey, Kenneth A Kern

Breast Cancer Res Treat· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Jonas Bergh, Gabriella Mariani, Fatima Cardoso, Annelie Liljegren, Ahmad Awada, Kenneth A Kern

Breast· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
Kiana Keyvanjah, Samuel E DePrimo, Charles S Harmon, Xin Huang, Kenneth A Kern

J Transl Med· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Jonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, Annelie Liljegren, Richard Greil, Kenneth A Kern

J Clin Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Nicholas J Robert, Mansoor N Saleh, Devchand Paul, Daniele Generali, Laurent Gressot, Kenneth A Kern

Clin Breast Cancer· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Carlos H Barrios, Mei-Ching Liu, Soo Chin Lee, Laurence Vanlemmens, Jean-Marc Ferrero, Kenneth A Kern

Breast Cancer Res Treat· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimally invasive operation for breast cancer.
S Eva Singletary, Kambiz Dowlatshahi, William Dooley, Scott T Hollenbeck, Kenneth Kern

Curr Probl Surg· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving the lowest false-negative rate in peritumoral breast lymphatic mapping: the oncologic search for the Holy Grail.
Kenneth A Kern

Ann Surg Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When medical error becomes medical malpractice: the victims and the circumstances.
Thomas F Tracy, Linda S Crawford, Thomas J Krizek, Kenneth A Kern

Arch Surg· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid.
Kenneth A Kern

J Am Coll Surg· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rational approach to internal mammary node biopsy in the era of lymphatic mapping for breast cancer.
Kenneth A Kern

J Surg Oncol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis